Social Media Press Releases

RSS

Showing Press Releases with Tag: monoclonal antibody

10/30/2009

MedImmune to Present 4 Abstracts on RSV and Influenza at 47TH Annual IDSA Meeting

» read more
6/29/2009

MedImmune Expands Access for Eligible Premature Infants to Receive Synagis(R) at No Cost

» read more
4/16/2009

MedImmune Showcases Commitment to Cancer Research at Annual Meeting of the American Association for Cancer Research

» read more
12/04/2008

MedImmune Advances Asthma Program With Start of Phase 2 Clinical Trial for Antibody Targeting IL-5 Receptor

» read more
11/28/2008

MedImmune Receives FDA Complete Response Letter on Motavizumab

» read more
10/24/2008

MedImmune to Present Nine Abstracts on RSV and Influenza at 48th Annual ICAAC/46th Annual IDSA Meeting

» read more
10/23/2008

MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology

» read more
10/11/2008

MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease

» read more
8/12/2008

MedImmune Initiates First Phase 2 Trial in Lupus Patients With its Antibody Targeting Interferon-alpha

» read more
6/12/2008

Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia

» read more
5/15/2008

Depth of MedImmune’s Respiratory Disease Research Program Highlighted at Annual Meeting of the American Thoracic Society

» read more
5/04/2008

Phase 3 Data Regarding Anti-RSV Antibody To Be Presented at Pediatric Academic Societies (PAS) Annual Meeting

» read more
4/15/2008

MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13

» read more
3/18/2008

MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma

» read more
2/04/2008

MedImmune Submits Biologics License Application to FDA for Motavizumab

» read more